Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$935 Mln
Revenue (TTM)
$727 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
1.1
Industry P/E
--
EV/EBITDA
-27.9
Div. Yield
0 %
Debt to Equity
0.6
Book Value
$32.5
EPS
$-4.2
Face value
--
Shares outstanding
129,812,211
CFO
$30.30 Mln
EBITDA
$122.24 Mln
Net Profit
$-233.72 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
NeoGenomics (NEO)
| -32.0 | -18.6 | -32.0 | -14.4 | -22.8 | -30.3 | 1.5 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
NeoGenomics (NEO)
| -28.6 | 1.8 | 75.1 | -72.9 | -36.6 | 84.1 | 132.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
NeoGenomics (NEO)
|
8.0 | 934.7 | 727.3 | -108.0 | -14.6 | -12.4 | -- | 1.1 |
| 14.0 | 3,317.6 | 3,125.0 | -262.7 | 0.9 | -313.2 | -- | 20.5 | |
| 380.6 | 5,369.9 | 2,530.0 | 265.2 | 14.2 | 25.3 | 20.8 | 5.3 | |
| 54.5 | 2,778.6 | 941.5 | 105.7 | 14.5 | 29.4 | 26.2 | 7.3 | |
| 97.4 | 9,799.0 | 5,935.2 | 566.2 | 18.1 | 25.1 | 17.5 | 4.0 | |
| 19.1 | 4,362.8 | 2,347.6 | 128.4 | 4.5 | 25.2 | 37.5 | 8.4 | |
| 27.5 | 4,285.8 | 5,649.5 | 207.6 | 7.0 | 15.2 | 21.3 | 3.3 | |
| 54.8 | 4,326.1 | 2,040.2 | -18.7 | 5.0 | -1.9 | -- | 4.0 | |
| 15.0 | 3,768.2 | 1,163.6 | 78.0 | 26.1 | 15.4 | 49.1 | 6.2 | |
| 196.6 | 11,646.4 | 5,057.8 | 344.0 | 9.2 | 16.9 | 34.4 | 5.2 |
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical... companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Address: 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912 Read more
CEO & Director
Mr. Christopher Michael Smith BSc
CEO & Director
Mr. Christopher Michael Smith BSc
Headquarters
Fort Myers, FL
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of NeoGenomics Inc (NEO) is $8.00 (NASDAQ) as of 02-Apr-2026 16:13 EDT. NeoGenomics Inc (NEO) has given a return of -22.83% in the last 3 years.
Since, TTM earnings of NeoGenomics Inc (NEO) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.80
|
0.36
|
|
2024
|
-5.30
|
0.46
|
|
2023
|
-4.63
|
0.43
|
|
2022
|
-1.60
|
0.23
|
|
2021
|
-100.62
|
0.76
|
The 52-week high and low of NeoGenomics Inc (NEO) are Rs 13.74 and Rs 4.72 as of 04-Apr-2026.
NeoGenomics Inc (NEO) has a market capitalisation of $ 935 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in NeoGenomics Inc (NEO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.25
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.